Matinas biopharma announces publication of results from the phase 2 enact clinical trial of mat2203 in the idsa journal clinical infectious diseases

Bedminster, n.j., aug. 22, 2023 (globe newswire) -- matinas biopharma (nyse american: mtnb), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (lnc) platform delivery technology, announces that university of minnesota medical school researchers published results from the phase 2 enact trial evaluating mat2203 for the treatment of cryptococcal meningitis as a major article and editor's choice in clinical infectious diseases, an official publication of the infectious diseases society of america (idsa). mat2203 is an oral and non-toxic, lnc formulation of the potent antifungal drug amphotericin b.
MTNB Ratings Summary
MTNB Quant Ranking